TLX Telix Pharmaceuticals Limited
Company Analysis
Latest News
Telix Launches Pixclara Commercially in U.S. After FDA Approval
Telix Pharmaceuticals has begun the U.S. commercial rollout of Pixclara, its newly FDA-approved brain cancer imaging agent. The first commercial doses were...
🟢 Telix Pharmaceuticals is trading 4.93% up in after-hours trading despite concerns over proposed ITM acquisition dilution
Telix Pharmaceuticals is trading at $11.83, up 4.93%, after regular-session losses tied to investor concerns about its proposed ITM acquisition. - The US$1.65...
🔴 Telix Pharmaceuticals is trading 5% down today as dilution concerns weigh on ITM deal
Telix Pharmaceuticals is trading at $11.36, down 5%, as investors reassess dilution from its proposed US$1.65 billion acquisition of ITM Isotope Technologies...
🟢 Telix Pharmaceuticals is trading 6.72% up today after announcing proposed US$1.65 billion acquisition of ITM
Telix Pharmaceuticals is trading 6.72% up now at $12.07 after announcing its proposed US$1.65 billion acquisition of ITM Isotope Technologies Munich. -...
🟢 Telix Pharmaceuticals is trading 4.77% up in pre-market after announcing US$1.65 billion ITM acquisition
Telix Pharmaceuticals is trading 4.77% up at $11.85 after announcing its US$1.65 billion acquisition of ITM Isotope Technologies Munich. • The transaction...
🔴 Telix Pharmaceuticals is trading 11.8% down today after announcing US$1.65 billion acquisition of ITM
Telix Pharmaceuticals is trading 11.8% down at $11.23 after announcing a US$1.65 billion acquisition of ITM Isotope Technologies Munich. - The transaction...
Telix Bets $1.65 Billion on a Radioactive Drug Supplier — But Will Shareholders Pay the Price for an FDA-Rejected Asset?
Shares plunged 11% to $11.21 as Telix Pharmaceuticals unveiled its largest-ever deal: a US$1.65 billion acquisition of Germany's ITM Isotope Technologies...
🔴 Telix Pharmaceuticals is trading 11% down in pre-market after announcing US$1.65 billion acquisition of ITM
Telix Pharmaceuticals is trading 10.96% down now at $11.21 in pre-market after announcing a US$1.65 billion acquisition of ITM Isotope Technologies Munich on...
🔴 Telix Pharmaceuticals is trading 4.7% down in pre-market after announcing US$1.65 billion ITM acquisition
Telix Pharmaceuticals is trading 4.7% down now at $12.00 after announcing a strategic agreement to acquire ITM Isotope Technologies Munich for US$1.65...
🟢 Telix Pharmaceuticals is trading 8% up today as markets recover after Fed's September 16 decision
Telix Pharmaceuticals is trading 7.51% up now at $12.58 as U.S. equities recover following the Federal Reserve’s September 16 rate decision. - The S&P 500 and...
🟢 Telix Pharmaceuticals is trading 5.49% up in pre-market as Nasdaq and S&P 500 rebound
Telix Pharmaceuticals is trading 5.49% up in pre-market at $12.48 after a broader pre-market recovery lifted major U.S. indexes. - Nasdaq Composite rose...
🔴 Telix Pharmaceuticals is trading 7.13% down today on profit-taking after Pixclara FDA approval
Telix Pharmaceuticals is trading 7.13% down at $11.91, apparently reflecting profit-taking after the September 14 FDA approval of Pixclara. - Shares rose...
🔴 Telix Pharmaceuticals is trading 4.1% down in pre-market — possible profit-taking after Pixclara approval
Telix Pharmaceuticals is trading 4.13% down at $12.30 in pre-market, possibly reflecting profit-taking after its approval-driven rally. - It rose 8.91% to...
🟢 Telix Pharmaceuticals is trading 10.03% up today after FDA approval of Pixclara for glioma imaging
Telix Pharmaceuticals is trading 10.03% up now at $12.96 after the U.S. FDA approved Pixclara on September 14, 2026, for glioma imaging. - Pixclara is the...
🟢 Telix Pharmaceuticals is trading 8.32% up today after FDA approval of Pixclara for glioma imaging
Telix Pharmaceuticals is trading 8.32% up at $12.76 after the U.S. FDA approved Pixclara on September 14, 2026, for glioma imaging. - Pixclara is the first...
🟢 Telix Pharmaceuticals is trading 4.16% up today after FDA approves Pixclara for glioma imaging
Telix Pharmaceuticals is trading 4.16% up at $11.73 after the FDA approved Pixclara for imaging gliomas. - Pixclara is the first FDA-approved FET-PET imaging...
Telix Wins Its First Brain-Cancer Drug Approval — But Can a Niche Imaging Product Move the Needle for a Billion-Dollar Business?
Shares jumped 7.2% to $12.10 as Telix Pharmaceuticals landed the first-ever FDA-approved imaging drug for brain cancer, handing the Australian...
🟢 Telix Pharmaceuticals is trading 7% up in pre-market after FDA approval of Pixclara for glioma imaging
Telix Pharmaceuticals is trading 7.17% up in pre-market at $12.10 after U.S. FDA approval of Pixclara. - Pixclara is indicated for PET imaging to...
🟢 Telix Pharmaceuticals is trading 6.54% up in after-hours trading as Pixclara’s PDUFA outcome remains unconfirmed
Telix Pharmaceuticals is trading 6.54% up at $12.03 in after-hours trading, supported by broader U.S. indexes gaining more than 0.5%. - It closed at $11.29 on...
🔴 Telix Pharmaceuticals is trading 4.37% down today despite broad U.S. market gains
Telix Pharmaceuticals is trading 4.37% down at $11.38 on September 11, 2026, despite broad U.S. market gains; the precise catalyst remains unclear. - The key...